Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for ICOSAPENT ETHYL
- Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Inflammatory Breast Cancer That Has Spread to Other Parts of the Body
- The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk
- A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults
- PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial
- An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19
- Long-term Safety and Efficacy Study of MND-2119 in Patients With Hypertriglyceridemia
- PRevention Using EPA Against coloREctal Cancer
- Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia
- PRevention Using EPA Against coloREctal Cancer
- Vascepa to Accelerate Lipoprotein Uptake and Elimination
- Efficacy of MND-2119 in Participants With Hypertriglyceridemia
- OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer
- EPA for Metastasis Trial 2
- Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer
- Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid
- PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA
- A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major
Clinical trials list
click for details